Why Zegluxen®?
Zegluxen® offers bioequivalent clinical efficacy and heritage of liraglutide in improving glycaemic control in patients with Type 2 diabetes mellitus (T2DM) alongside diet and exercise1,2
Zegluxen® offers bioequivalent clinical efficacy and heritage of liraglutide in improving glycaemic control in patients with Type 2 diabetes mellitus (T2DM) alongside diet and exercise1,2
ASSURED SAVINGS
Potential cost savings of up to 35% versus Victoza® /generic liraglutide solution for injection in pre-filled pens3
CONSISTENT SUPPLY
Zentiva work hand-in-hand with our customers to forecast future stock requirements to ensure patients receive the medications they need
DEDICATED PATIENT SUPPORT
Dedicated HCP and patient support materials
BMI, Body Mass Index; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, haemoglobin A1c; SmPC, Summary of Product Characteristics
1. Zegluxen® (liraglutide) Summary of Product Characteristics.
2. Liraglutide bioequivalence. Data on File. Zentiva, August 2024.
3. NHS Business Services Agency. Drug Tariff Category C price. NHS Electronic Drug Tariff. drugtariff.nhsbsa.nhs.uk Savings are based on August 2024 Drug Tariff.
000697546 | December 2024